These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 34435592)

  • 1. The influence of CYP2C19*2 and CYP3A5*3 variants on the development of depression and effectiveness of therapy: A preliminary study.
    Świechowski R; Jeleń A; Pietrzak J; Gałecki P; Szmajda-Krygier D; Balcerczak E
    Biomed Pharmacother; 2021 Oct; 142():112055. PubMed ID: 34435592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
    Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
    Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Association of CYP2C19 and CYP3A5 gene polymorphisms with myocardial infarction].
    Qi L; Liang W; Qiao H; Wang R; Han J; Xing X; Hu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Jan; 38(1):87-91. PubMed ID: 33423267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population.
    Krasniqi V; Dimovski A; Bytyqi HQ; Eftimov A; Šimičević L; Božina N
    Arh Hig Rada Toksikol; 2017 Sep; 68(3):180-184. PubMed ID: 28976882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele.
    Hwang IC; Park JY; Ahn HY; Kim KK; Suh HS; Ko KD; Kim KA
    Clin Chim Acta; 2014 Jan; 428():77-81. PubMed ID: 24262967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
    Kim HS; Lim Y; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    Br J Clin Pharmacol; 2016 Feb; 81(2):301-12. PubMed ID: 26426352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors.
    Zhu L; Liao S; Wang N; Ge T; Yang J; Xu G; Wang J; Li K; Li G
    Int J Clin Pharmacol Ther; 2016 Aug; 54(8):587-96. PubMed ID: 27191765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
    Arya V; Mahajan P; Saraf A; Mohanty A; Sawhney JP; Bhargava M
    Int J Lab Hematol; 2015 Dec; 37(6):809-18. PubMed ID: 26264906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.
    Lee HI; Byeon JY; Kim YH; Lee CM; Choi CI; Jang CG; Bae JW; Lee YJ; Lee SY
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1417-1426. PubMed ID: 30039199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
    Yoo HD; Cho HY; Lee YB
    Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population.
    Vargas-Alarcón G; Ramírez-Bello J; de la Peña A; Calderón-Cruz B; Peña-Duque MA; Martínez-Ríos MA; Ramírez-Fuentes S; Pérez-Méndez O; Fragoso JM
    Mol Biol Rep; 2014 Oct; 41(10):7023-9. PubMed ID: 25106522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
    Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
    Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.
    Kumaraswami K; Katkam SK; Aggarwal A; Sharma A; Manthri R; Kutala VK; Rajasekhar L
    Pharmacogenomics; 2017 Oct; 18(15):1401-1411. PubMed ID: 28976264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
    Velazquez MNR; Parween S; Udhane SS; Pandey AV
    Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions.
    Nakkam N; Tiamkao S; Kanjanawart S; Tiamkao S; Vannaprasaht S; Tassaneeyakul W; Tassaneeyakul W
    Drug Metab Pharmacokinet; 2015 Aug; 30(4):295-304. PubMed ID: 26099919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel.
    Rodríguez-González F; Martínez-Quintana E; Saavedra P; Medina-Gil JM; Riaño M; Garay-Sánchez P; Tugores A
    J Clin Pharmacol; 2018 Oct; 58(10):1274-1283. PubMed ID: 29723426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.
    Sugimoto K; Uno T; Tateishi T
    Eur J Clin Pharmacol; 2008 Jun; 64(6):583-7. PubMed ID: 18214455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
    Yi X; Lin J; Wang Y; Zhou Q; Wang C; Cheng W; Chi L
    J Atheroscler Thromb; 2016 Oct; 23(10):1188-1200. PubMed ID: 26961113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.